Dai­ichi Sankyo inks $183M dis­cov­ery deal with GPCR biotech for CNS tar­get

Bel­gian biotech Con­fo Ther­a­peu­tics has land­ed $183 mil­lion, plus po­ten­tial roy­al­ties, in a drug-dis­cov­ery deal with Dai­ichi Sankyo.

Ear­ly Thurs­day, Con­fo Ther­a­peu­tics put out word of the deal that will be fo­cused on small mol­e­cule an­tag­o­nists to go af­ter an undis­closed tar­get that the com­pa­ny says is as­so­ci­at­ed with CNS dis­eases.

Con­fo CEO Cedric Ververken told End­points News that Dai­ichi orig­i­nal­ly reached out to learn about the biotech’s tech­nol­o­gy. He added that Con­fo, found­ed in 2015, will use its plat­form to drug a GPCR tar­get that Dai­ichi has strug­gled with in­ter­nal­ly.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN